AstraZeneca Chief Executive Officer David Brennan has been elected board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Pfizer has appointed Martin Mackay as president, PharmaTherapeutics Research Group, and Mikael Dolsten as president, BioTherapeutics Research Group. Emilio Emini will join Pfizer as chief scientific officer, Vaccine Research, and Menelas Pangalos will join Pfizer as chief scientific officer, Neuroscience Research.
Orexigen Therapeutics has appointed Michael Narachi as president and CEO.
Astellas Pharma has named Seigo Kashii as president and CEO of North American operations. His predecessor, Yoshihiko Hatanaka, will become the chief strategy officer and chief financial officer of Astellas' Tokyo operations.
A. Collier Smyth, M.D., has been appointed to the board of directors of ARIAD Pharmaceuticals.
Seattle Genetics has appointed Vaughn B. Himes, Ph.D., as executive vice president , technical operations and promoted Morris Z. Rosenberg, D.Sc., to executive vice president , process sciences.
Joel Jung has resigned as chief financial officer of Celera and will be replaced by Ugo DeBlasi.
Cerulean Pharma has named Oliver S. Fetzer as president and CEO and elected Alan L. Crane as chairman of the board.
Samuel R. Saks, CEO and a member of the board of directors at Jazz Pharmaceuticals, has resigned from both positions. Executive Chairman Bruce C. Cozadd has been elected CEO and Jazz President Robert M. Myers will replace Saks on the board of directors.
Infinity Pharmaceuticals announced the promotion of John J. Keilty to vice president, information technology and informatics, and Joseph F. McPherson to vice president, facilities and operations.
NovaBay Pharmaceuticals has elected Professor John A. Soderquist to the company's scientific advisory board.
RXi Pharmaceuticals announced that Ramani Varanasi, MS, MBA has joined the company as vice president of business operations; Stephen DiPalma, MBA has been promoted from chief financial officer to executive vice president of business operations and chief financial officer; and Joanne Kamens, Ph.D., formerly directory of discovery research, has been named senior director.
David J. Williams, retired chairman and CEO of Sanofi Pasteur, has joined Xcellerex's board of directors.
Solvay Pharma has appointed Barry Hayter as general manager, Canada.
TransMolecular announced the appointment of Robert Radie as president and CEO, as well as the promotion of E. Michael Egan, former president and CEO, to the position of vice chairman of the board.
Life science investment manager Richard van den Broek has been elected to the board of directors at Pharmaxis.
Rochelle Seide, Ph.D., J.D. has been named vice president, intellectual property for Biovail Laboratories International.
N30 Pharma has named Dr. Augustine Choi, Dr. Michael Marletta, Dr. William Sessa, and Dr. Joseph Vita to its scientific advisory board, which will be chaired by Dr. Joseph Loscalzo.